06/02/2026 Biologics as add-on therapy for severe asthma
The Ministry of Health’s Drug Advisory Committee has recommended:
- Benralizumab 30 mg/1 mL aut...
06/02/2026 Biologics as add-on therapy for severe asthma
The Ministry of Health’s Drug Advisory Committee has recommended:
- Benralizumab 30 mg/1 mL autoinjector pen for treating severe eosinophilic asthma; and
- Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for treating severe allergic asthma.
Funding status
RBenralizumab 30 mg/ml autoinjector pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
RBenralizumab should be used in line with the additional clinical criteria for initiation and renewal listed in the Annex.
ROmalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes are recommended for inclusion on the Standard Drug List (SDL) from 1 April 2026.
NRSDL subsidy and MAF assistance do not apply to any formulations or strengths of dupilumab, mepolizumab, omalizumab reference biologic (Xolair) or tezepelumab for treating severe asthma.
02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Abrocitinib 50 mg, 100 mg a...
02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.
Funding status
RAbrocitinib 50 mg, 100 mg and 200 mg film-coated tablets are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.
RAbrocitinib should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with moderate-to-severe atopic dermatitis.
NRMAF assistance does not apply to any formulations or strengths of baricitinib, upadacitinib or dupilumab for treating atopic dermatitis.